NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study

NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study

Background Immunotherapies targeting the programmed death receptor-1/programmed death ligand-1(PD-1/PD-L1) checkpoint have a major impact on the treatment of both resectable and advanced non-small cell lung cancer (NSCLC). Additional blockade of the T-cell immunoreceptor with immunoglobulin and immu...

Full description

Saved in:
Bibliographic Details
Main Authors: Albrecht Stenzinger, Farastuk Bozorgmehr, Michael Thomas, Hauke Winter, Michael Allgäeuer, Alexander Schramm, Servet Bolukbas, Marietta Kirchner, Martin Schuler, Petros Christopoulos, Marc Schneider, Romina M Roesch, Johannes Schnorbach, Laura V Klotz, Raffaella Griffo, Marcel Wiesweg, Fabian Doerr, Balazs Hegedüs, Jelena Cvetkovic, Martin E Eichhorn, Florian Eichhorn
Format: Article
Language:English
Published: BMJ Publishing Group 2025-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/3/e096617.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/15/3/e096617.full

Similar Items